Literature DB >> 9663452

Differential effects of intracerebroventricular glucagon-like peptide-1 on feeding and energy expenditure regulation.

J J Hwa1, L Ghibaudi, P Williams, M B Witten, R Tedesco, C D Strader.   

Abstract

Intracerebroventricular (i.c.v.) administration of glucagon-like peptide-1-(7-37) amide (GLP-1) has been shown to modulate food and water intake. The present studies further characterize the effects of i.c.v. GLP-1 in the regulation of energy balance in lean and obese animals. In both obese and lean Zucker rats, a single i.c.v. infusion of GLP-1 (1-30 microg) resulted in a dose-dependent reduction of food intake and decrease in respiratory quotient relative to the saline control during the first 2 h of the nocturnal cycle. In obese Zucker rats, the food intake was reduced by 73 +/- 11% of the control at the 30 microg dose, whereas a modest 45 +/- 18% reduction was observed in lean rats. Despite the large reduction in food intake seen with GLP-1, there was no compensatory decrease in nocturnal oxygen consumption in the obese Zucker rats. Interestingly, low doses of GLP-1 (1 microg) in lean Zucker rats, which had minimal effects on food intake, caused a 19 +/- 7% increase in O2 consumption during the first 2 h of the nocturnal cycle. These data suggest that central GLP-1 may be an important factor controlling negative energy balance in both the lean and obese Zucker rats.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9663452     DOI: 10.1016/s0196-9781(98)00033-3

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  18 in total

Review 1.  Regulation of energy balance by a gut-brain axis and involvement of the gut microbiota.

Authors:  Paige V Bauer; Sophie C Hamr; Frank A Duca
Journal:  Cell Mol Life Sci       Date:  2015-11-05       Impact factor: 9.261

Review 2.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 3.  Gut hormones ghrelin, PYY, and GLP-1 in the regulation of energy balance [corrected] and metabolism.

Authors:  Diego Perez-Tilve; Ruben Nogueiras; Federico Mallo; Stephen C Benoit; Matthias Tschoep
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

4.  Glucagon-like peptide-1 regulates brown adipose tissue thermogenesis via the gut-brain axis in rats.

Authors:  Jean-Philippe Krieger; Ellen Paula Santos da Conceição; Graciela Sanchez-Watts; Myrtha Arnold; Klaus G Pettersen; Mazher Mohammed; Salvatore Modica; Pius Lossel; Shaun F Morrison; Christopher J Madden; Alan G Watts; Wolfgang Langhans; Shin J Lee
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-05-30       Impact factor: 3.619

Review 5.  Glucagon-like peptide 1 (GLP-1) and metabolic diseases.

Authors:  C M Rotella; L Pala; E Mannucci
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

6.  Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial.

Authors:  Alessio Basolo; Joshua Burkholder; Kristy Osgood; Alexis Graham; Sarah Bundrick; Joseph Frankl; Paolo Piaggi; Marie S Thearle; Jonathan Krakoff
Journal:  Metabolism       Date:  2018-03-26       Impact factor: 8.694

Review 7.  Gastrointestinal hormones and polycystic ovary syndrome.

Authors:  Jing Ma; Tzu Chun Lin; Wei Liu
Journal:  Endocrine       Date:  2014-05-04       Impact factor: 3.633

Review 8.  Surgical weight loss: impact on energy expenditure.

Authors:  David Thivel; Katrina Brakonieki; Pascale Duche; Béatrice Morio; Morio Béatrice; Yves Boirie; Boirie Yves; Blandine Laferrère
Journal:  Obes Surg       Date:  2013-02       Impact factor: 4.129

Review 9.  Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

Authors:  David J Grieve; Roslyn S Cassidy; Brian D Green
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

10.  Olfactory bulb-targeted quantum dot (QD) bioconjugate and Kv1.3 blocking peptide improve metabolic health in obese male mice.

Authors:  Austin B Schwartz; Anshika Kapur; Zhenbo Huang; Raveendra Anangi; John M Spear; Scott Stagg; Erminia Fardone; Zolan Dekan; Jens T Rosenberg; Samuel C Grant; Glenn F King; Hedi Mattoussi; Debra Ann Fadool
Journal:  J Neurochem       Date:  2020-10-20       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.